Insulin docking within the open hemichannel of connexin 43 may reduce risk of amyotrophic lateral sclerosis

Steven Lehrer, MD
Department of Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York

Peter H. Rheinstein, MD, JD, MS
Severn Health Solutions
Severna Park, Maryland

correspondence to Dr. Steven Lehrer, Box 1236 Radiation Oncology, Mount Sinai Medical Center, 1 Gustave L. Levy Place, New York 10029 or steven.lehrer@mssm.edu

Keywords: amyotrophic lateral sclerosis, insulin, diabetes

Funding sources: Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award numbers S10OD018522 and S10OD026880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai.

Data sources described in article all publicly available.

Conflicts of interest: none

Dr. Lehrer and Dr. Rheinstein contributed equally to the conception, writing, and data analysis of this study.

Abstract

Background: Type 2 diabetes (T2D), characterized by hyperinsulinemia, protects motor neurons against amyotrophic lateral sclerosis (ALS). Type 1 diabetes and a total lack of insulin are associated with increased risk of ALS. Connexin 43 (Cx43), an astrocyte protein, operates as an open pore via which toxic substances from the astrocytes reach the motor neurons.

Methods: In the current study we performed molecular docking of insulin with monomeric Cx31, monomeric Cx43, and hexameric Cx31 to assess whether insulin might affect the pore. Hexameric Cx31 and hexameric Cx43 have hemichannels composed of 6 subunits that work as transmembrane channels, binding together to form gap junction intercellular channels that open and close. We used the program AutoDock Vina Extended for the molecular docking study.

Results: Cx31 shares amino acid and structural similarity to Cx43 and insulin docks to the same position of the N-terminal domain of monomeric Cx31 and monomeric Cx43. Insulin docks within the open hemichannel of hexameric Cx31, potentially blocking it. The block may be responsible for the protective relationship of T2D to ALS.

Conclusion: Insulin might be a treatment for ALS, especially since insulin enhances glucose-stimulated insulin secretion in healthy humans. An insulin secretogogue such as oral sulfonylurea or glinide might also be of value.

Amyotrophic lateral sclerosis (ALS) is a disease of motor neurons that affects up to 30,000 people in the United States each year, with 5,000 new cases being diagnosed. Muscles become weaker over time, affecting physical function, and eventually leading to death. The condition has no single cause and no recognized remedy.

Type 2 diabetes (T2D), but not type 1, protected against ALS in a Danish population-based study [1]. A Swedish population study identified a significant inverse association between ALS and T2D, but not type 1 diabetes, with the strongest inverse association 6 years after diabetes onset [2]. An Italian cohort study revealed a significantly reduced ALS risk in T2D (hazard ratio 0.30) with no effect of gender, age, or ALS phenotype [3]. Zhang et al reported that genetically predicted T2D was associated with significantly lower odds of ALS both in European and East Asian populations [4]. Type 1 diabetes, characterized by a total lack of insulin, is associated with increased risk of ALS [1, 2].

Connexin 43 (Cx43), an astrocyte protein (also called Gap junction alpha-1 protein, GJA1), operates as an open pore via which toxic substances from the astrocytes reach the motor neurons. Patients with ALS who had a family history of the disease and those who had sporadic ALS had the most functional pores [5].

Connexin 31 (Cx31) shares amino acid and structural similarity to Cx43 [7, 8]. In their hexameric form, both connexins are composed of 6 subunits that work as transmembrane channels, binding together to form gap junction intercellular channels that open and close.

Hyperinsulinemia is a hallmark of T2D [6]. In the current study we performed molecular docking of insulin with the Cx43 monomer and Cx31 monomer. We then performed molecular docking of insulin with the Cx31 hexamer (also called Gap junction beta-3 protein, GJB3) to assess whether insulin might affect the pore.

Methods

We used the program AutoDock Vina Extended for the docking study [9]. AutoDock Vina Extended achieves an approximately two orders of magnitude acceleration compared with the molecular docking software AutoDock 4, while also significantly improving the accuracy of the binding mode predictions. Further speed is achieved from parallelism, by using multithreading on multicore machines. AutoDock Vina Extended automatically calculates the grid maps and clusters the results in a way transparent to the user. UCSF Chimera 1.14 was used for molecular visualization [10].

The insulin molecule (humulin B) is from PubChem CID101896409. Human hexameric Cx31 hemichannel in the absence of calcium was deposited in the RCSB Protein Data Bank (6L3T) 2019-10-15, released: 2020-09-09.

Cx43 had no entry in the RCBS Protein Data Bank for the complete molecule. We obtained a protein structure prediction for Cx43 (GJA1) from AlphaFold, an artificial intelligence (AI) system developed by Google's DeepMind that predicts a protein's 3D structure from its amino acid sequence. AlphaFold regularly achieves accuracy competitive with experiment [11, 12].

Cx31 had no entry in the RCBS Protein Data Bank for the monomer. We obtained a monomeric protein structure prediction for Cx31 (GJB3) from AlphaFold.

Results

Figure 1A shows Cx43 in AlphaFold, which produces a per-residue confidence score (pLDDT) between 0 and 100. Figure 1B displays predicted aligned error in Alpha Fold. Figure 1C shows CX31 in AlphaFold. Figure 1D displays Cx31 predicted aligned error in Alpha Fold.

Figure 2A shows human Cx43 in its monomeric form docked with insulin. Arrows indicate the insulin molecule docked to the Cx43 N-terminal domain. Figure 2B is a closeup of the docked insulin molecule. Figure 2C shows human Cx31 in its monomeric form docked with insulin. Arrows indicate the insulin molecule docked to the Cx31 N-terminal domain. Figure 2D is a closeup of the docked insulin molecule. Note that insulin docks to almost the identical position in monomeric Cx31 and monomeric Cx43.

Figure 3 illustrates binding affinity (kcal/mol) calculated for 10 docking sites, insulin docked to monomeric Cx43. Only the one site with the highest affinity (upper left in figure) was a valid position.

Table 1 contains docking parameters calculated by AutoDock Vina Extended, monomeric Cx43 to insulin. Lower values of root-mean-square deviations of atomic positions (RMSD) indicate that docking is validated with higher accuracy. RMSD values of 3 or more indicate no docking has occurred. One docking position, mode 1, with RMSD = 0 is highly valid.

Figure 4 shows binding affinity (kcal/mol) calculated for 10 docking sites, insulin to monomeric Cx31. Only one site with the highest affinity (upper left) was a valid position.

Table 2 contains docking parameters calculated by AutoDock Vina Extended, monomeric Cx31 to insulin. One docking position, mode 1, with RMSD = 0 is highly valid.

Figure 5A shows human Cx31 in its hexameric form docked with insulin. Arrows indicate the insulin molecule docked within the hemichannel. Figure 5B is a closeup of the docked insulin molecule.

Figure 6 illustrates binding affinity (kcal/mol) calculated for 10 docking sites, insulin docked to hexameric Cx31. Only the one site in the hemichannel with the highest affinity (upper left in figure) was a valid position.

Table 3 contains docking parameters calculated by AutoDock Vina Extended, hexameric Cx31 to insulin. One docking position, mode 1, with RMSD = 0 is highly valid.

Discussion

Cx43 is normally expressed in astrocytes and found in most human astrocytomas and in the astroglial component of glioneuronal tumors [13]. Astrocytes may cause the death of motor neurons since astrocyte dysfunction occurs after symptom onset in patients with ALS. Astrocytes provoke motor

neuron death through Cx43 hemichannels that allow the movement of toxic astrocyte substances into motor neurons. Cx43 protein is elevated in cerebrospinal fluid of ALS patients and could be a biomarker [5].

Because astrocytes may be responsible for the progression of ALS, drugs that block Cx43 hemichannels might be therapeutic [5]. The Cx43 N-terminal domain is involved in channel gating and oligomerization, and may control the switch between the channel's open and closed states. Therefore, the docking of insulin to the Cx43 N-terminal domain we demonstrate here may be capable of blocking the channel, preventing toxic astrocyte substances from entering and destroying motor neurons.

Our finding that insulin docks within the open hemichannel of hexameric Cx31, potentially blocking it, again suggests that the block may be responsible for the inverse relationship between ALS and T2D. This conclusion is reinforced by the fact that insulin docks to the same position, the N-terminal domain, of monomeric Cx31 and monomeric Cx43 (Figure 2). Therefore, insulin might be a treatment for ALS, especially since insulin enhances glucose-stimulated insulin secretion in healthy humans [14]. Type 1 diabetes, characterized by a total lack of insulin, is associated with increased risk of ALS [1, 2], again suggesting that insulin could have a beneficial effect on ALS. An insulin secretogogue such as oral sulfonylurea or glinide might also be of value.

However, this hypothesis has weaknesses:

1) Zhang et al did not observe a significant association between 2 h glucose, fasting glucose, fasting insulin, fasting proinsulin, HbA1C and the risk of ALS in European populations [4]. But the Cx43 gene, GJA1, has multiple polymorphisms, and some may affect Cx43 interaction with insulin [15].
2) Insulin docks almost identically within monomeric Cx31 and monomeric Cx43. We assume that insulin docks identically within hexameric Cx31 and hexameric Cx43, but this may not be the case. Cx31 abnormalities are associated with erythrokeratoderma, a rare skin condition [16].

In sum, the docking results presented here indicate that insulin may be capable of inhibiting the progression of ALS by blocking Cx43 hemichannels. Further study is warranted.

References

[1] Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG (2015) Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study. *JAMA Neurol* **72**, 905-911.

[2] Mariosa D, Kamel F, Bellocco R, Ye W, Fang F (2015) Association between diabetes and amyotrophic lateral sclerosis in Sweden. *Eur J Neurol* **22**, 1436-1442.
[3] D'Ovidio F, d'Errico A, Carna P, Calvo A, Costa G, Chio A (2018) The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. *Eur J Neurol* **25**, 164-170.
[4] Zhang L, Tang L, Huang T, Fan D (2022) Association between type 2 diabetes and amyotrophic lateral sclerosis. *Sci Rep* **12**, 2544.
[5] Almad AA, Taga A, Joseph J, Gross SK, Welsh C, Patankar A, Richard JP, Rust K, Pokharel A, Plott C, Lillo M, Dastgheyb R, Eggan K, Haughey N, Contreras JE, Maragakis NJ (2022) Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS. *Proc Natl Acad Sci U S A* **119**, e2107391119.
[6] Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE (2000) A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. *Diabetes* **49**, 2094-2101.
[7] Hawat G, Baroudi G (2012) Connexin 43 Hemichannels and Pharmacotherapy of Myocardial Ischemia Injury In *Novel Strategies in Ischemic Heart Disease* IntechOpen.
[8] Lee HJ, Jeong H, Hyun J, Ryu B, Park K, Lim HH, Yoo J, Woo JS (2020) Cryo-EM structure of human Cx31.3/GJC3 connexin hemichannel. *Sci Adv* **6**, eaba4996.
[9] Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem* **31**, 455-461.
[10] Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* **25**, 1605-1612.
[11] Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M, Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW, Kavukcuoglu K, Kohli P, Hassabis D (2021) Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583-589.
[12] Komaroff AL (2021) Breakthrough Discovery in Protein Structure Prediction and the Promise of New Treatments. *JAMA*.
[13] Aronica E, Gorter JA, Jansen GH, Leenstra S, Yankaya B, Troost D (2001) Expression of connexin 43 and connexin 32 gap-junction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. *Acta Neuropathol* **101**, 449-459.
[14] Bouche C, Lopez X, Fleischman A, Cypess AM, O'Shea S, Stefanovski D, Bergman RN, Rogatsky E, Stein DT, Kahn CR, Kulkarni RN, Goldfine AB (2010) Insulin enhances glucose-stimulated insulin secretion in healthy humans. *Proc Natl Acad Sci U S A* **107**, 4770-4775.
[15] Zhang J, You Q, Shu J, Gang Q, Jin H, Yu M, Sun W, Zhang W, Huang Y (2020) GJA1 Gene Polymorphisms and Topographic Distribution of Cranial MRI Lesions in Cerebral Small Vessel Disease. *Front Neurol* **11**, 583974.
[16] Charfeddine C, Laroussi N, Mkaouar R, Jouini R, Khayat O, Redissi A, Mosbah A, Dallali H, Chedly Debbiche A, Zaouak A, Fenniche S, Abdelhak S, Hammami-Ghorbel H (2021) Expanding the clinical phenotype associated with NIPAL4 mutation: Study of a Tunisian consanguineous family with erythrokeratodermia variabilis-Like Autosomal Recessive Congenital Ichthyosis. *PLoS One* **16**, e0258777.



Figure 1A. Cx43 (also called Gap junction alpha-1 protein, GJA1) in AlphaFold, which produces a per-residue confidence score (pLDDT) between 0 and 100 (lower left). Figure 1B. Predicted aligned error. The color at position (x, y) indicates AlphaFold's expected position error at residue x, when the predicted and true structures are aligned on residue y. The shade of green indicates expected distance error in Ångströms. The color at (x, y) corresponds to the expected distance error in residue x's position, when the prediction and true structure are aligned on residue y. Dark green is good (low error), light green is bad (high error). 1C. Cx31 (also called Gap junction beta-3 protein, GJB3) in AlphaFold. Figure 1D. Predicted Cx31 aligned error.



Figure 2A. Human Cx43 in its monomeric form docked with insulin at the Cx43 N-terminal domain. Arrow indicates the insulin molecule. 2B. Closeup of Cx43 docked to insulin molecule. Per residue confidence score (pLDDT) from AlphaFold of the N-terminal domain (Figure 1A) is *confident,* 90 < pLDDT <70. 2C. Human Cx31 in its monomeric form docked with insulin at the Cx31 N-terminal domain. Arrow indicates the insulin molecule. 2D. Closeup of Cx31 docked to insulin molecule. Per residue confidence score (pLDDT) from AlphaFold of the N-terminal domain (Figure 1C) is *confident,* 90 < pLDDT <70. Note that insulin docks to almost the identical position in monomeric Cx31 and monomeric Cx43.

mode	affinity (kcal/mol)	Ki(µmol)	RMSD lower bound(Å)	RMSD upper bound(Å)
1	-6.074602412	35.26029	0	0
2	-6.065978959	35.77725	27.73112185	31.15029382
3	-6.065369451	35.81407	2.902005898	8.116629233
4	-5.824558059	53.77367	1.92658046	7.437705569
5	-5.805591846	55.52288	2.733718603	8.206586658
6	-5.759997329	59.96433	2.771359767	8.194987559
7	-5.735407323	62.50541	2.208205522	5.237036912
8	-5.617848751	76.22346	2.149206141	7.494382604
9	-5.477866589	96.53755	15.877928	19.02405307
10	-5.420853417	106.2887	2.428831289	5.403085509

Table 1. Docking parameters calculated by AutoDock Vina Extended for human monomeric Cx43 to insulin. Lower values of root-mean-square deviations of atomic positions (RMSD) indicate that docking is validated with higher accuracy. RMSD values of 3 or more indicate no docking has occurred. One docking position, mode 1, with RMSD = 0 is highly valid.



Figure 3. Binding affinity (kcal/mol) calculated for 10 docking sites, insulin to monomeric Cx43. Only one site with the highest affinity (upper left) was a valid position.

mode	affinity (kcal/mol)	Ki(µmol)	RMSD lower bound(Å)	RMSD upper bound(Å)
1	-5.764226326	59.53785	0	0
2	-5.604354028	77.97948	20.29215496	24.5788459
3	-5.50895568	91.6026	24.13479769	26.64546373
4	-5.487040562	95.05428	24.10361311	28.26772351
5	-5.469198364	97.9603	25.81208942	28.4784468
6	-5.431554356	104.3863	19.49592317	23.8544476
7	-5.358509811	118.0825	3.708488437	4.594993627
8	-5.344926538	120.8209	24.15928651	26.64988346
9	-5.274514921	136.0674	25.04492059	29.83058177
10	-5.244106707	143.2331	25.62035767	28.69788407

Table 2. Docking parameters calculated by AutoDock Vina Extended for human monomeric Cx31 to insulin. One docking position, mode 1, with RMSD = 0 is highly valid.

Figure 4. Binding affinity (kcal/mol) calculated for 10 docking sites, insulin to monomeric Cx31. Only one site with the highest affinity (upper left) was a valid position.



Figure 5A. Human Cx31 in its hexameric form with open hemichannel (center) docked with insulin. Arrows indicate the insulin molecule within the hemichannel. 5B. Closeup of docked insulin molecule.

mode	affinity (kcal/mol)	Ki(µmol)	RMSD lower bound(Å)	RMSD upper bound(Å)
1	-6.499765043	17.2044	0	0
2	-6.498996353	17.22674	8.738951896	10.75563818
3	-6.49403788	17.37151	16.04060202	18.62194177
4	-6.480787951	17.76437	8.710319846	10.73125405
5	-6.479632275	17.79906	18.41293941	21.47099771
6	-6.448499272	18.75934	16.05073372	18.60996308
7	-6.150886428	31.00055	28.43659168	33.35036486
8	-6.073789675	35.30869	22.76797584	26.71361825
9	-6.056759246	36.33834	34.99424228	38.79479813
10	-6.038860805	37.45283	40.62664359	44.9530327

Table 3. Docking parameters calculated by AutoDock Vina Extended of hexameric Cx31 to insulin. One docking position, mode 1, with RMSD = 0 is highly valid.



Figure 6. Binding affinity (kcal/mol) calculated for 10 docking sites, insulin to Cx31 hexamer. Only one site with the highest affinity (upper left) was a valid position.